Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors-Reference-Cited by-同舟云学术

Trimer form of tumor necrosis factor-related apoptosis inducing ligand induces apoptosis in canine cell lines derived from mammary tumors

Published:2019 Issue:12 Volume:81 Page:1791-1803
ISSN:0916-7250
Container-title:Journal of Veterinary Medical Science
language:en
Short-container-title:The Journal of Veterinary Medical Science

Author:

GOTO Minami¹,HIRATA Akihiro¹²,MURAKAMI Mami³,SAKAI Hiroki¹⁴

Affiliation:

1. Laboratory of Veterinary Pathology, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan

2. Division of Animal Experiment, Life Science Research Center, Gifu University, 1-1 Yanagido, Gifu 501-1194, Japan

3. Joint Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan

4. Center for Highly Advanced Integration of Nano and Life Sciences, Gifu University, 1-1 Yanagido, Gifu 501-1193, Japan

Publisher

Japanese Society of Veterinary Science

Subject

General Veterinary

Link

https://www.jstage.jst.go.jp/article/jvms/81/12/81_19-0469/_pdf

Reference51 articles.

1. 1. Abdelmegeed, S. M. and Mohammed, S. 2018. Canine mammary tumors as a model for human disease . Oncol. Lett. 15: 8195–8205.

2. 2. Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., DeForge, L., Koumenis, I. L., Lewis, D., Harris, L., Bussiere, J., Koeppen, H., Shahrokh, Z. and Schwall, R. H. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104: 155–162.

3. 3. Bongiovanni, L., Romanucci, M., Malatesta, D., D’Andrea, A., Ciccarelli, A. and Della Salda, L. 2015. Survivin and related proteins in canine mammary tumors: immunohistochemical expression. Vet. Pathol. 52: 269–275.

4. 4. Buchsbaum, D. J., Zhou, T., Grizzle, W. E., Oliver, P. G., Hammond, C. J., Zhang, S., Carpenter, M. and LoBuglio, A. F. 2003. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9: 3731–3741.

5. 5. Cheng, A. L., Kang, Y. K., He, A. R., Lim, H. Y., Ryoo, B. Y., Hung, C. H., Sheen, I. S., Izumi, N., Austin, T., Wang, Q., Greenberg, J., Shiratori, S., Beckman, R. A., Kudo, M., Investigators’ Study Group 2015. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study. J. Hepatol. 63: 896–904.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ELF3 plays an important role in defining TRAIL sensitivity in breast cancer by modulating the expression of decoy receptor 2 (DCR2);Molecular Biology Reports;2024-05-24

2. Tumour necrosis factor ‐related apoptosis‐inducing ligand (TRAIL) loss in canine mammary carcinoma;Veterinary and Comparative Oncology;2021-09-15